Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...3435363738394041424344...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pre-treatment With Ranibizumab Aggravates PDT Injury and Alleviates Inflammatory Response in Choroid-Retinal Endothelial Cells. (Pubmed Central) -  Aug 1, 2020   
    Pre-treatment with rani promotes PDT-caused apoptosis via triggering caspase 8-mediated extrinsic apoptosis, and caspase 8 might also play a pivotal role in the rani's function of suppressing PDT-induced necroptosis and NLRP3 inflammasome activation. Our results implicate that pre-treatment with rani may enhance the angio-occlusive efficiency of PDT and alleviate endothelial inflammatory response, which gives it a great advantage over post-treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  "Para-retinal" Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression. (Pubmed Central) -  Jul 24, 2020   
    AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa), and the large size impedes diffusion to reach the retina from the usual injection site in the anterior/mid-vitreous...More efficient retinal delivery translates to using lower vector doses, with reduced risk of ocular inflammatory exposure. These results indicate that para-retinal delivery yields more effective vector concentration near the retina, thereby increasing the potential for better retinal transduction in human clinical application.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Efficiency analysis by mfERG and OCT of intravitreal injection with ranibizumab on diabetic macular edema. (Pubmed Central) -  Jul 21, 2020   
    These results indicate that para-retinal delivery yields more effective vector concentration near the retina, thereby increasing the potential for better retinal transduction in human clinical application. OCT and mfERG fully demonstrate the importance of IVR for DME patients from the macular morphology and function, especially the significance of mfERG in this disease.
  • ||||||||||  NN1213 / Novo Nordisk, Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Trial completion, Trial completion date:  TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) -  Jul 14, 2020   
    P2/3,  N=55, Completed, 
    These data may help in further study of noninvasive imaging biomarkers for better evaluation of treatment response. Active, not recruiting --> Completed | Trial completion date: May 2020 --> Dec 2019
  • ||||||||||  Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) -  Jul 14, 2020   
    P=N/A,  N=62, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2020 --> Dec 2019 Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Glucose Metabolic Characterization of Human Aqueous Humor in Relation to Wet Age-Related Macular Degeneration. (Pubmed Central) -  Jul 7, 2020   
    In total, 25 eyes of 25 patients with wAMD were divided into phakic (15 eyes), pseudophakic (10 eyes), and intravitreal injections of ranibizumab (13 eyes) wAMD groups...Compromised glucose TCA cycle and altered glutamine metabolism are implicated in the AH metabolism in wAMD. These findings highlight potential treatments for alleviating wAMD from a metabolic perspective.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. (Pubmed Central) -  Jul 2, 2020   
    No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Ranibizumab in macular oedema secondary to branch retinal vein occlusion - 24 months of treatment. (Pubmed Central) -  Jul 2, 2020   
    In this study, the effect of ranibizumab on functional and morphological parameters of the affected eye was monitored, the safety of this treatment was also evaluated. During the follow-up, a statistically significant improvement in VA was achieved in every visit in comparison to baseline parameters, the mean VA gain at the 3 month visit was 12,1 ETDRS letters (p.
  • ||||||||||  Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
    Trial completion date, Trial primary completion date:  XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) -  Jul 1, 2020   
    P3,  N=580, Recruiting, 
    During the follow-up, a statistically significant improvement in VA was achieved in every visit in comparison to baseline parameters, the mean VA gain at the 3 month visit was 12,1 ETDRS letters (p. Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: May 2020 --> Nov 2020
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Jun 25, 2020   
    P4,  N=150, Not yet recruiting, 
    Repeated intravitreal injections of 0.5 mg of ranibizumab or 2 mg of aflibercept can influence the morphology of the corneal endothelium but not CCT. Trial completion date: Mar 2021 --> Jun 2021 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2020 --> Mar 2021
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Anti-vascular endothelial growth factor for neovascular glaucoma. (Pubmed Central) -  Jun 25, 2020   
    Currently available evidence is uncertain regarding the long-term effectiveness of anti-VEGF medications, such as intravitreal ranibizumab or bevacizumab or aflibercept, as an adjunct to conventional treatment in lowering IOP in NVG. More research is needed to investigate the long-term effect of these medications compared with, or in addition to, conventional surgical or medical treatment in lowering IOP in NVG.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    New P3 trial:  CoRaLa II: Combination of Ranibizumab and Targeted Laser Photocoagulation (clinicaltrials.gov) -  Jun 22, 2020   
    P3,  N=110, Not yet recruiting, 
    We suggest that there is no need to combine macular grid photocoagulation in the treatment of ME secondary to BRVO in the future. .
  • ||||||||||  Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) -  Jun 16, 2020   
    P=N/A,  N=80, Recruiting, 
    This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs031180210). Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration. (Pubmed Central) -  Jun 14, 2020   
    From the data of 48 treatment-naïve nAMD eyes that received intravitreal ranibizumab pro re nata for up to 12 months, we used the aqueous humour concentrations of C-X-C motif chemokine ligand 1 (CXCL1), CXCL12, CXCL13, interferon-γ-induced protein 10, monocyte chemoattractant protein 1 (MCP-1), C-C motif chemokine ligand 11, interleukin 6 (IL-6), IL-10, and matrix metalloproteinase 9 (MMP-9)...High MMP-9 at the first injection (β coefficient = 0.56, P = 0.01), CXCL12 at the third injection (β coefficient = 0.10, P = 0.0002), and IL-10 at the third injection (β coefficient = 1.3, P = 0.001) were predictor variables associated with the increased number of injections. In conclusion, aqueous humour protein concentrations may have predictive abilities of BCVA change over 12 months and the number of injections in pro re nata treatment of exudative nAMD.